Press release / For immediate circulation
Montreal, Quebec – October 11, 2016
Health Canada greenlights MendeliKABS for the commercialization of PrMDK-Nitisinone™.
MendeliKABS is proud to announce that Health Canada has approved MDK-Nitisinone medication for the treatment of hereditary tyrosinemia type 1. This is Health Canada’s first approval for a hereditary tyrosinemia type 1 medication. Nitisinone is used to treat hereditary tyrosinemia type 1 in combination with adherence to a reduced tyrosine dietary regime. Since its introduction in 1991, this treatment has replaced liver transplantation as a first line treatment for patients with this rare condition.
Classified as an orphan disease, hereditary tyrosinemia type 1 affects one person out of 200,000 worldwide, but is especially prevalent in Québec with about one hundred persons affected.
The challenge of well-being for all
Inspired by the principle of offering premium quality affordable solutions to persons afflicted with hereditary tyrosinemia type 1, MendeliKABS’ vision embraces expanded access to orphan drugs in order to effectively meet the needs of patients affected by rare diseases. Produced in three dosages, 2 mg, 5 mg and 10 mg, MDK-Nitisinone is manufactured in Quebec.
“At a point in time when access to medications has become an increasingly sensitive issue, we are particularly proud to be able to offer the first and only treatment approved by Health Canada for Canadians suffering from tyrosinemia,” said Dr Bruno Maranda, President of MendeliKABS.
For more information
Tel: 514-600-1623 / 1-888 959-9987 extension 101
4601, rue de Tonnancour
Longueuil (Quebec) Canada J3Y 9J3